Smruthi Organic Share Price & Earnings Call Analysis

Financials of Smruthi Organic

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Smruthi Organic

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +36.7834.9129.5923.4839.6627.2729.3931.2538.0918.9931.6022.2929.09
Expenses +34.5330.2925.1624.6635.5826.8226.5027.0833.4118.7626.5918.2925.30
Operating Profit2.254.624.43-1.184.080.452.894.174.680.235.014.003.79
OPM %6.12%13.23%14.97%-5.03%10.29%1.65%9.83%13.34%12.29%1.21%15.85%17.95%13.03%
Other Income +0.050.010.000.000.060.000.010.000.080.090.01-0.440.01
Interest0.250.330.390.320.370.410.440.510.520.460.660.250.31
Depreciation1.241.241.381.451.591.291.331.371.501.411.511.671.75
Profit before tax0.813.062.66-2.952.18-1.251.132.292.74-1.552.851.641.74
Tax %14.81%25.49%22.56%-22.03%30.73%-26.40%31.86%35.37%18.61%-29.03%27.72%14.63%38.51%
Net Profit +0.692.292.07-2.291.52-0.920.781.482.23-1.102.061.401.07
EPS in Rs0.602.001.81-2.001.33-0.800.681.291.95-0.961.801.220.93

Financials of Smruthi Organic

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +77747997137131126133141128126102
Expenses +726369941211169811513111611489
Operating Profit5111031715291810121213
OPM %6%14%13%3%12%12%23%14%7%9%10%13%
Other Income +00101411000-0
Interest654443111122
Depreciation544444445666
Profit before tax-623-5101224144555
Tax %-33%55%39%-31%30%30%29%25%8%28%27%27%
Net Profit +-412-37817104443
EPS in Rs-3.340.631.39-2.826.027.4114.959.073.613.143.113.00
Dividend Payout %0%0%0%0%11%14%20%33%55%48%48%0%

Financials of Smruthi Organic

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital444444111111111111
Reserves262728253339495657586062
Borrowings +453733312816103612178
Other Liabilities +343520253730211832372322
Total Liabilities1091038585101889288106118112104
Fixed Assets +353230303032313337404547
CWIP111120112133
Investments000000000000
Other Assets +726954546956605366776453
Total Assets1091038585101889288106118112104

Financials of Smruthi Organic

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +9149512212321241022
Cash from Investing Activity +-10-0-3-4-5-37-10-7-11-9
Cash from Financing Activity +-8-14-9-2-5-17-7-12-231-12
Net Cash Flow-1-0002-113-30-0-01
Free Cash Flow7138171719-43-4-214
CFO/OP184%128%93%159%71%160%101%33%136%46%100%182%

Financials of Smruthi Organic

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10395979597686278961179469
Inventory Days12316614512692751009196150151228
Days Payable1061281231301209781509814485111
Cash Conversion Cycle1201331199268468011893123160186
Working Capital Days28177832529973949285
ROCE %0%9%10%-1%21%25%39%21%7%8%8%8%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd